Page data last changed: . Chemistry registry snapshot: . Registry refreshes and identity assessments are separate from scientific content review.
Tachykinin family peptide — central to nociception research.
Part of the Neuropeptides & signaling cluster
Overview
Substance P is an 11-amino-acid neuropeptide of the tachykinin family involved in pain signaling and neurogenic inflammation research.
Source & context
Biological / chemical source: Nervous system
Primary research or clinical context: Pain research
Sequence motif
The C-terminal FXGLM-amide motif is characteristic of tachykinins and important for receptor interaction at NK1 and related receptors.
Sequence
One-letter sequence commonly cited for Substance P (educational; isoforms and modifications may differ):
RPKPQQFFGLM
Residues plotted ~100° apart around an α-helix — clustering of one color reveals an amphipathic face.
Structure & chemistry
Molecular identity & reference confidence
Source-supported reference
Reference values are taken from the cited molecular record or curated profile. A database match is not independent laboratory verification; modifications, counter-ions, and formulations can change the measured mass.
- Molecular form
- Substance P (source record; form not independently established)
- Species
- Not established by this molecular identity audit
- Termini (N / C)
- Not specified / Not specified
Average reference mass
Reference policy updated: 2026-10-05
- IUPHAR/BPS source snapshot · 2026-10-01
- PubChem molecular record · 2026-10-01
- Molecular formula
- C63H98N18O13S
- Average reference mass
- ≈ 1,347.6
- PubChem CID: 36511
- IUPHAR ligand: 2098
- ChEMBL: CHEMBL235363
- CAS RN: 33507-63-0
- UNII: 675VGV5J1D
Chemistry values: PubChem, IUPHAR/BPS Guide to Pharmacology · fetched 2026-10-01.
Clinical development snapshot
ClinicalTrials.gov lists 150 registered studies with “Substance P” as an intervention (snapshot 2026-10-01). A registry footprint is not evidence of efficacy or approval.
| NCT | Title | Phase | Status | Updated |
|---|---|---|---|---|
| NCT07227597 | A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Ca | Phase 2 | recruiting | 2026-10-01 |
| NCT07286149 | A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) | Phase 2 | recruiting | 2026-10-01 |
| NCT07844772 | Serum Substance P, Neuropathic Pain, and Central Sensitization Across Treatment Groups in Chronic Plaque Psori | — | recruiting | 2026-09-28 |
| NCT07585721 | Postoperative Pain and Substance P Levels After Bioceramic vs Calcium Hydroxide Intracanal Medicaments in Symp | Not applicable | recruiting | 2026-09-25 |
| NCT04028492 | Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis | Phase 3 | completed | 2026-09-24 |
| NCT07832032 | Biological Profiles of Neuropeptides, Neurotrophins and miRNA in Migraine | — | not yet recruiting | 2026-09-21 |
Substance P — reconstitution calculator
Enter how much peptide is in the vial and how much diluent (e.g. bacteriostatic water) is added. The tool returns the resulting solution concentration — and, for any amount you type, the volume it corresponds to. This is educational arithmetic, not a dosing recommendation.
Reference form: Substance P (source record; form not independently established)Average reference mass: 1,347.6 Da
Enter an amount to see the volume it corresponds to.
Educational concentration mathematics only. This tool does not recommend a dose, amount, or protocol, and nothing here is medical advice. Many peptides are not authorized by Health Canada for human use — see our reconstitution and bacteriostatic-water guides for context.
Change log
Dated observations from the data pipeline (registry flags, trial footprints, identifiers) and editorial reviews of this profile.
- Trials2 registered studies added on ClinicalTrials.gov (now 150).
FAQ about Substance P
What is Substance P?+
Substance P is an 11-amino-acid neuropeptide of the tachykinin family involved in pain signaling and neurogenic inflammation research.
What Canadian product status is recorded for Substance P?+
Canadian product status for Substance P has not been verified in this profile. No verified record here does not mean no authorization exists. Status depends on the product, formulation and use; consult Health Canada's product records.
What is the typical length of Substance P?+
Substance P is commonly described as approximately 11 amino acids (Neuropeptide).
Related peptides
References & further reading
- 1.Pernow (1983). Substance P. Pharmacol Rev
- 2.Snijdelaar et al. (2000). Substance P. Eur J Pain
- 3.Iversen (1982). Substance P. Br Med Bull
- 4.Mroz et al. (1977). Substance P. Vitam Horm
- 5.Leeman et al. (1974). Substance P. Life Sci
- 6.Sandberg et al. (1982). Substance P. J Med Chem
- 7.Redkiewicz (2022). The Regenerative Potential of Substance P. Int J Mol Sci
- 8.Bernstein et al. (1981). Substance P. J Invest Dermatol
- 9.PubChem — compound summary for Substance P (CID 36511)
- 10.Wikipedia — Substance P